home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

22.35 UNCHANGED

Streaming Delayed Price Updated: 4:15 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

33 34 Next >

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

July 04, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Sarepta Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds SRPT Stockholders of the Lead Plaintiff Deadline in the SRPT Class Action Lawsuit

July 03, 2025

From Robbins LLP

Via GlobeNewswire

SRPT INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Sarepta Class Action Lawsuit

July 03, 2025

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Shareholders That Lost Money on Sarepta Therapeutics, Inc. (SRPT) Should Contact Levi & Korsinsky About Pending Class Action - SRPT

July 03, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Shareholders That Lost Money on Sarepta Therapeutics, Inc. (SRPT) Should Contact Levi & Korsinsky About Pending Class Action - SRPT

July 03, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT

July 02, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT

July 02, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 02, 2025

Via Benzinga

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

July 02, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

July 01, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

July 01, 2025

From Pomerantz LLP

Via GlobeNewswire

SAREPTA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm

June 30, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Shareholder Alert: Robbins LLP Informs Investors of the Sarepta Therapeutics, Inc. Class Action

June 30, 2025

From Robbins LLP

Via GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 30, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

June 30, 2025

Via ACCESS Newswire

SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) INVESTOR ALERT: Investors With Large Losses in Sarepta Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

June 30, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

June 28, 2025

From Pomerantz LLP

Via GlobeNewswire

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

June 28, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Rosen Law Firm Urges Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

June 27, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

SRPT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Sarepta Class Action Lawsuit

June 27, 2025

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

2 Beaten-Down Stocks to Avoid ↗

June 27, 2025

Via The Motley Fool

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

June 26, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

June 26, 2025

From The Schall Law Firm

Via Business Wire

SRPT SECURITIES NOTICE: Sarepta Therapeutics, Inc. Investors May Have Been Affected by Fraud - Contact BFA Law if You Suffered Losses

June 26, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

June 26, 2025

Via ACCESS Newswire

Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny ↗

June 25, 2025

FDA is investigating Sarepta's Elevidys after two deaths from liver failure in non-ambulatory DMD patients, raising safety and regulatory concerns.

Via Benzinga

Topics Death

Sarepta Therapeutics Is Already Down 84% This Year. And The Other Shoe Just Dropped. ↗

June 25, 2025

Shares were under pressure again Wednesday, deepening the 84% loss for the year, as the FDA planned the next steps for Elevidys.

Via Investor's Business Daily

Topics Death

Sarepta Stock Slumps After FDA Opens Probe Into Patient Death, Analyst Sounds Alarm ↗

June 25, 2025

H.C. Wainwright reiterated a ‘Sell’ rating on Sarepta on Wednesday with a $10 price target. The firm views the FDA as a potential headwind for Sarepta now.

Via Stocktwits

Topics Artificial Intelligence Death

This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday ↗

June 25, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

June 25, 2025

Via ACCESS Newswire

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com